ANN ARBOR, Michigan, May 1, 2026, 14:01 EDT
- ARCHIMED is set to acquire Esperion Therapeutics for $3.16 per share in cash, plus a non-tradeable contingent value right tied to future sales milestones.
- ESPR jumped roughly 56%, ending up just shy of the cash offer. Still, the shares hardly reflect most of the possible extra payout.
- Esperion has struck this deal only weeks after acquiring Corstasis and bringing Enbumyst, a nasal spray diuretic for excess fluid, into its portfolio.
ARCHIMED is buying Esperion Therapeutics Inc. in a transaction valued at up to $1.1 billion, the companies said Friday. Shares of Esperion jumped on the Nasdaq after word got out that the Michigan drugmaker is set to go private.
Esperion investors are set to receive $3.16 in cash for each share—58% higher than the stock’s April 30 close—along with a contingent value right attached to every share. That CVR could mean extra cash down the line, tied to future milestones and possibly amounting to a $100 million payout.
Esperion’s stock traded at $3.115 by 1:44 p.m. EDT, up a sharp 55.75% for the day and hovering just under the announced cash offer, according to market data. The market’s been quick to close that gap.
Esperion is working to shore up its commercial operations with the new deal. For 2025, net product sales hit $159.6 million, driven by its cholesterol treatments Nexletol and Nexlizet, while collaboration revenue landed at $243.6 million. The company still ended up $22.7 million in the red.
Esperion CEO Sheldon Koenig described the ARCHIMED deal as offering “attractive and immediate upfront value” to shareholders, and signaled there’s still a shot at future milestone payments. Justin Bateman, a partner at ARCHIMED, cited Esperion’s “strong foundation” across cardiovascular and primary care markets. Esperion Therapeutics, Inc.
Value questions hinge on the CVR. Should bempedoic-acid drugs—think Nexletol, Nexlizet—pull in $300 million in U.S. net sales in 2027, holders could see up to $40 million, maxing out at $350 million in sales. There’s also a potential $60 million tied to bumetanide products such as Enbumyst, but that’s only triggered if U.S. net sales hit $160 million in any year before Dec. 31, 2030.
Kristen Kluska at Cantor Fitzgerald called the deal underwhelming, especially with Esperion’s U.S. peak sales estimates around $1.5 billion. She raised questions around the company’s real potential for grabbing market share. On her math, if peak sales landed at $500 million, Esperion shares would likely have hovered at $3 before the buyout.
Esperion zeroes in on LDL-C—the so-called “bad” cholesterol. The company’s main offerings, Nexletol and Nexlizet, are both non-statin pills taken once a day. They’re aimed at patients struggling to lower their LDL-C and still facing heart risks. Esperion Therapeutics, Inc.
In March, the company took steps to expand its cardiovascular offerings, laying out plans to buy Corstasis Therapeutics, developer of Enbumyst—a bumetanide nasal spray. Esperion says the spray received FDA approval in September 2025 for treating edema in adults with congestive heart failure, liver disease, or kidney disease.
Competition remains intense. Esperion’s annual report flags tough, established players: cheap generic statins, ezetimibe, and injectable PCSK9s—Amgen’s Repatha, Regeneron and Sanofi’s Praluent, plus Novartis’ Leqvio. ARCHIMED picks up a commercial asset here, but far from a monopoly.
Even so, investors banking on the full payout face a stack of risks. Esperion shareholders haven’t given their approval, and the deal must still clear U.S. antitrust review and secure a key non-U.S. green light. A handful of closing conditions linger. Per the 8-K, those CVRs aren’t tradeable, come with no voting or dividend rights, and if the milestones fall short, could end up worth nothing.
Esperion’s board signed off on the deal with every director in favor, pushing shareholders to approve it too. The company is eyeing a third-quarter close. After that, Esperion will exit the public markets, dropping its Nasdaq ticker.
